Charles River Laboratories | CRL - Ebitda

Stock Price
202.87
Daily Change
1.46 0.72%
Monthly
-2.62%
Yearly
24.37%
Q1 Forecast
204.00

Charles River Laboratories reported $282.89M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Agilent USD 466M 5M Jun/2025
Align Technology USD 203.61M 66M Jun/2025
Bio-Rad Laboratories USD 467.2M 372.2M Jun/2025
Bruker USD 128.1M 27.1M Jun/2025
Cardinal Health USD 986M 319M Sep/2025
Charles River Laboratories USD 282.89M 64.81M Sep/2025
Cigna USD 2.86B 56M Mar/2025
CVS Health USD 4.09B 392M Sep/2025
Danaher USD 2.13B 252M Dec/2025
Dentsply International USD 167M 30M Sep/2025
Elevance Health USD 2.19B 1.01B Sep/2025
Galapagos EUR -158.71M 177.84M Mar/2025
Hologic USD 330.4M 16.6M Dec/2025
Humana USD 824M 546M Sep/2025
Illumina USD 332M 12M Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
IQVIA Holdings USD 949M 39M Sep/2025
Laboratory Of America USD 633.6M 135.6M Jun/2025
Lonza CHF 1.01B 54M Dec/2025
McKesson USD 1.68B 418M Sep/2025
Merck EUR 1.46B 45M Jun/2025
Mettler Toledo International USD 322.64M 26.75M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Quest Diagnostics USD 561M 9M Sep/2025
Revvity USD 248.91M 48.52M Dec/2025
Thermo Fisher Scientific USD 3.17B 335M Dec/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
UnitedHealth USD 1.5B 3.92B Dec/2025
Waters USD 295.14M 18.87M Sep/2025
West Pharmaceutical Services USD 213.1M 14.6M Sep/2025